Title: Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy1

Principal Investigators: Brian Van Tine, MD, PhD, Washington University School of Medicine

Continue Reading

Description: For this phase 2, single group assignment study, researchers are attempting to determine whether cryoablation, radiofrequency ablation, or microwave ablation are feasible, safe, and effective methods of treating patients with metastatic sarcoma that is stable on chemotherapy.

Patients with metastatic osteosarcoma or sarcoma that has not progressed on 6 to 12 cycles of chemotherapy are eligible. Depending on tumor characteristics, patients will undergo microwave ablation, cryoablation, or radiofrequency ablation. Patients will also be asked to fill out pain surveys and quality of life questionnaires.

The primary outcome measure is progression-free survival. Secondary measures include overall survival, change in quality of life, and level of pain.

RELATED: Trial of Radiotherapy for Lung Metastases in Soft Tissue Sarcoma

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01986829.

Status: This study is open and recruiting patients as of April 19, 2017.

This study is sponsored by the Washington University School of Medicine.


  1. Clinicaltrials.gov. Cryoablation, radiofrequency ablation, or microwave ablation in treating patients with metastatic sarcoma stable on chemotherapy. NCT01986829. https://clinicaltrials.gov/ct2/show/NCT01986829. Accessed April 19, 2017.